Aim: Vaccination against SARS-CoV2 has been proposed as a fundamental element for the control of the pandemic. The aim of this study is to describe the suspected adverse reactions (ADRs) reported among vaccinated hospital workers. Methods: Descriptive study of suspected ADRs identified between January and March 2021. The suspected ADRs were identified by specifically designed electronic form and by spontaneous reporting. Data was also collected regarding the characteristics of the professionals, vaccine administered, severity, and outcome of the ADR. Results: 8,169 professionals received the two doses of SARS-CoV2 vaccine (6,672 Comirnaty® and 1,497 Spikevax®) and 894 reports of suspected ADR were reported (762 for Comirnaty® and 132 for Spikevax®), so a cumulative AEFIs incidence of 10.94% (95%CI: 10.27-11.62). The majority of ADRs were reported only after the second dose, 497(56.2%) while 211 (23.6%) was reported only after the first dose and a 186 (21%) after both doses. Symptoms were mostly mild, did not require medical assistance and disappeared in about 3 days. One hundred and seventeen professionals had a history of COVID-19. These reported, statistically significant, more suspected ADRs after the first dose (42.7%) than professionals with no history of COVID-19 (20.7%). Among the professionals, more ADRs occurred after the first dose with the Spikevax® vaccine (41.6%) than with the Comirnaty® vaccine (20.5%). Conclusion: The majority of the suspected ADRs reported were those described in the summary of product characteristics (SmPC). Professionals with history of COVID-19 reported more suspected ADRs after the first dose than professionals without history.